XSHE
300573
Market cap1.90bUSD
Oct 09, Last price
35.55CNY
1D
-0.31%
1Q
-12.42%
Jan 2017
45.70%
IPO
508.73%
Name
Shenyang Xingqi Pharmaceutical Co Ltd
Chart & performance
P/E
18.25
P/S
5.14
EPS
1.95
Div yield, %
2.73%
Shrs. gr., 5y
24.66%
Rev. gr., 5y
29.13%
Revenues
2.47b
+27.24%
Net income
696m
+105.84%
CFO
753m
+80.68%
Dividend
Sep 23, 20260.3 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shenyang Xingqi Pharmaceutical Co., Ltd, based in Shenyang, China, specializes in the comprehensive process of creating, producing, and distributing ophthalmological products throughout the Chinese market. The company offers a diverse portfolio of eye care solutions, which includes items for corneal health, anti-bacterial applications, artificial tear substitutes, anti-inflammatory medications, surgical perfusion liquids, mydriatic agents, anti-fatigue treatments, and specific therapies for both incipient and severe dry eye conditions.
Key people
Jidong Liu
Chairman of the Board · since 2022
Shaoyao Zhang
Vice Chairman of the Board, Deputy General Manager, Secretary of the Board · since 2022
Chunhua Li
Chief Administrative Officer, Director · since 2022
Yanan Cheng
Chief Financial Officer, Deputy General Manager, Director · since 2024
Qiang Yang
Deputy General Manager, Director, Head of R&D Center · since 2022
E Gao
General Manager, Director · since 2022
Xiaobin Dai
Independent Director · since 2021
Xiaoyan Kong
Independent Director · since 2024
Xianmei Xu
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||